Congress-IPS
Congress-IPS-Mobile

Acute Hepatic Porphyria (AHP)

American Association for the Study of Liver Diseases (AASLD) 2025

Congress Details

calanderNovember 7-11, 2025

locationWashington, D.C.

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

agenda icon

Congress Materials

AASLD-Oral-Presentation-Clinical-outcomes-and-hemin-use-of-patients-with-acute-hepatic-porphyria-in-the-phase-3-ENVISION-study-who-were-not-attack-free-after-6-months-of-givosiran-treatment
icon Presentation Type
Presentation
location icon Location
Washington, D.C.
icon Title
Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment
AASLD-2025-Clinical-outcomes-and-hemin-use-of-patients-with-acute-hepatic-porphyria-in-the-phase-3-ENVISION-study
icon Presentation Type
Poster
location icon Location
Washington, D.C.
icon Title
Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment
AASLD-2025-Dimension-analysis-of-ENVISION-study-EQ-5D-data-to-assess-relationship-between-annualized-attack-rate
icon Presentation Type
Poster
location icon Location
Washington, D.C.
icon Title
Dimension analysis of ENVISION study EQ-5D data to assess relationship between annualized attack rate and chronic symptoms in patients with acute hepatic porphyria
AASLD-2025-EXPLORE-B-post-hoc-analysis-of-chronic-symptoms-in-patients-with-acute-hepatic-porphyria
icon Presentation Type
Poster
location icon Location
Washington, D.C.
icon Title
EXPLORE B post hoc analysis of chronic symptoms in patients with acute hepatic porphyria

Related Materials

Acute Hepatic Porphyria (AHP)

EXPLORE B: A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptoms

Journal of Inherited Metabolic Disease

Author(s)

David Cassiman, Raili Kauppinen, Susana Monroy

September 2022

Acute Hepatic Porphyria (AHP)

Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran

Expert Review of Gastroenterology & Hepatology

Author(s)

Paolo Ventura, Eliane Sardh, Nicola Longo, et al

August 2022

Acute Hepatic Porphyria (AHP)

Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study

Orphanet Journal of Rare Diseases

Author(s)

Bruce Wang, Paolo Ventura, Kei-Ichiro Takase, et al

August 2022

Acute Hepatic Porphyria (AHP)

Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts

Advances in Therapy

Author(s)

Kristen Wheeden, Desiree Lyon Howe, Sue Burrell, et al

July 2022

Acute Hepatic Porphyria (AHP)

A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver

Clinical Pharmacology and Therapeutics

Author(s)

Daphne Vassiliou, Eliane Sardh, Pauline Harper, et al

September 2021

Acute Hepatic Porphyria (AHP)

Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels

JIMD Reports

Author(s)

Sagar Agarwal, Bahru Habtemarium, Yuanxin Xu, et al

October 2020